Families of patients with recurrent head‑and‑neck cancers are traveling abroad for a single‑session, needle‑free radiation treatment that promises to spare healthy tissue, but U.S. insurers still balk at covering it because the clinical data are limited and the cost of installing a neutron‑beam system runs into the millions.
How Boron Neutron Capture Therapy Works
BNCT is a binary radiotherapy. First, patients receive an intravenous infusion of a boron‑10‑containing drug, most often the approved compound Steboronine® (borofalan [¹⁰B]). The drug preferentially accumulates in tumor cells. Then the tumor is bathed in an epithermal neutron beam generated by an accelerator‑based system. When boron‑10 captures a thermal neutron, it undergoes fission, releasing high‑energy alpha particles and lithium‑7 nuclei that travel only 5 to 10 micrometers—about the diameter of a single cell—so the lethal radiation is confined to the boron‑laden cancer cells.
From Reactors to Accelerators
Early BNCT trials relied on nuclear reactors to produce neutrons. Modern centers use compact accelerators that create higher‑energy epithermal neutrons, eliminating the need for a full‑scale reactor and making the technology more feasible for hospitals. Companies such as Heron Neutron Medical are expanding accelerator‑based BNCT (AB‑BNCT) platforms worldwide, pairing them with diagnostic agents like [¹⁸F]FBPA that map boron uptake before irradiation.
Clinical Outcomes for Recurrent Head‑and‑Neck Cancers
BNCT has been evaluated for locally invasive malignant tumors, including recurrent head‑and‑neck cancers. In China, the Panboron BNCT hospital in Hainan has completed nearly 60 treatments since its first patient on May 20, 2026, treating patients from 20 provinces and overseas in a single‑visit session. The therapy is delivered in one neutron irradiation, and early reports indicate tumor control in many cases, though comprehensive survival data are still pending.
Why U.S. Coverage Remains Elusive
Hospitals must invest heavily in accelerator equipment, shielding, and specialized staff—costs that can exceed several million dollars per installation. Medicare and private insurers require robust evidence of cost‑effectiveness and long‑term outcomes before approving reimbursement. To date, most BNCT data come from single‑institution trials or early‑phase studies, lacking the large, randomized cohorts that insurers typically demand. Without clear reimbursement pathways, many U.S. centers cannot justify the capital outlay, leaving patients to seek care abroad.
What This Means for Patients and Families
For families facing recurrent disease, BNCT offers a treatment that avoids additional surgery or conventional radiation, potentially preserving quality of life. However, the financial barrier is steep: patients must either locate a center that can absorb the cost or shoulder travel expenses similar to those Australian families face for other emerging technologies. Until more extensive trial data and cost‑effectiveness analyses are published, U.S. coverage decisions are likely to stay the same.
The next milestone for BNCT in China is the planned expansion of the Hainan facility’s patient intake in early 2027, as the center aims to increase its treatment volume and collect longer‑term outcome data.
Sources
- Australians spending up to $100k overseas to access cancer technology
- Neutron capture therapy of cancer
- Automated Precursor Evaluation Optimizes Boron Cancer Diagnostic Imaging
- Heron Neutron Medical to Acquire 50.09% Stake in Singapore's SAM Holdings for NT$1.38 Billion — BigGo Finance
- Panboron BNCT Opens Cross-Border BNCT Care Pathway in China
Photo: sandro porfirio / Unsplash (Unsplash License)





